Nevro Corp Stock News
$9.79
-0.720 (-6.85%)
At Close: May 10, 2024
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
04:58pm, Friday, 05'th Aug 2022 Zacks Investment Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
02:18pm, Friday, 05'th Aug 2022
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
Where Nevro Stands With Analysts
05:44pm, Thursday, 04'th Aug 2022 Benzinga
Over the past 3 months, 6 analysts have published their opinion on Nevro (NYSE:NVRO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's b
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
11:25pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Nevro (NVRO) delivered earnings and revenue surprises of 12.35% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
09:03pm, Wednesday, 03'rd Aug 2022
Nevro (NVRO) delivered earnings and revenue surprises of 12.35% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Nevro to Present at the Canaccord Genuity 42nd Annual Growth Conference
07:00am, Thursday, 21'st Jul 2022
Wednesday, August 10, 2022 at 2:30 pm Eastern Time REDWOOD CITY, Calif. , July 21, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, lif
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
04:16pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
01:54pm, Thursday, 23'rd Jun 2022
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery
02:00am, Friday, 10'th Jun 2022
Nevro is the top pure play spinal cord stimulation [SCS] company with three major industry competitors. Nevro's recent FDA approvals for its high frequency SCS system in treatment of painful diabetic
Expert Ratings for Nevro
05:12pm, Tuesday, 07'th Jun 2022 Benzinga
Over the past 3 months, 6 analysts have published their opinion on Nevro (NYSE:NVRO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's b
Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat
03:15pm, Monday, 09'th May 2022 Zacks Investment Research
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.
Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat
12:47pm, Monday, 09'th May 2022
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.
Nevro Corp. (NVRO) CEO Keith Grossman on Q1 2022 Results - Earnings Call Transcript
02:03pm, Saturday, 07'th May 2022
Nevro Corp. (NYSE:NVRO ) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Julie Dewey - Corporate Communications and Investor Relations Officer Keith Grossman - Chairman, Ch
Where Nevro Stands With Analysts
08:37pm, Thursday, 05'th May 2022 Benzinga
Nevro (NYSE:NVRO) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
2
4
1
0
Last 30D
0
0
2
0
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
10:25pm, Wednesday, 04'th May 2022 Zacks Investment Research
Nevro (NVRO) delivered earnings and revenue surprises of 11.71% and 2.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
